Oral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
An individual patient data metanalysis suggests that oral SERDs improve progression-free survival in ESR1 mutant subgroup, with no significant benefit in ESR1 wild type patients
Molecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
A study from Michelangelo Foundation researchers in collaboration with San Raffaele Hospital offers new insights for the treatment of high proliferation/low ER-signaling breast cancers based on molecular features
New data from Michelangelo Foundation’s NeoTRIP trial discussed during ESMO Congress
No Event-free survival improvement by addition of atezolizumab to neoadjuvant chemotherapy in NeoTRIP study but in a subset of triple negative breast cancer with a newly identified predictor restricted to benefit from the anti-PD-L1 antibody
Neratinib, fulvestrant and trastuzumab in HER2-mutant metastatic breast cancer
The SUMMIT study shows that the combination of neratinib, fulvestrant and trastuzumab is effective in HER2-mutant metastatic breast cancer after progression on CDK4/6 inhibitors
Breast cancer screening in women age 40-49
A canadian study shows that screening programs for women in their 40s increase breast cancer net survival but not the rate of breast cancer diagnosis
Determinants of trastuzumab deruxtecan response in metastatic breast cancer
The phase 2 DAISY trial suggests that HER2 expression is determinant of trastuzumab deruxtecan efficacy, but additional mechanisms may be involved
A genomic assay for adjuvant chemotherapy choice in early breast cancer
Oncotype DX helps to decrease discordancy in adjuvant chemotherapy recommendations in early stage breast cancer
In early breast cancer a temporary interruption of endocrine therapy to attempt pregnancy is feasible
Among selected patients with previous hormone receptor–positive early breast cancer, temporary interruption of endocrine therapy to attempt pregnancy did not rise short-term risk of breast cancer events
Targeting an unexpected vulnerability p53-inactivated triple negative breast cancer
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast cancer cells and suggests a new potential therapeutic target
Trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: results from DESTINY-Breast02
Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable benefit-risk profile in patients with HER2+ metastatic breast cancer
